Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Feng-Cai Zhu

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
Zhongguo Yi Miao He Mian Yi|August 24, 2010
[Research progress of influenza type A(H1N1) vaccine and monitoring adverse reaction]Wei-wei Zhang, Liang Li, Feng-cai Zhu
Expert Review of Vaccines|October 1, 2016
Vaccine profile of PPV23: Beijing Minhai Biotech 23-valent pneumococcal vaccineQi Liang, Gui-Fan Li, Feng-Cai Zhu
Zhongguo Yi Miao He Mian Yi|January 21, 2010
[Safety and immunogenicity of rabies vaccine (chick embryo cell) for human use produced in Germany and India]Feng-Cai Zhu, Chuan-Hong Wu, Fan-Yue Meng
Human Vaccines & Immunotherapeutics|April 5, 2019
The vaccines-associated Arthus reactionBaozhen Peng, Mingwei Wei, Feng-Cai Zhu, et al.
Expert Review of Vaccines|May 27, 2017
Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpointsWenbo Zhu, Pengfei Jin, Jing-Xin Li, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|April 17, 2003
[Surveillance on hemorrhagic fever with renal syndrome in Jiangsu province from 1996 to 2000]Rong-qiang Zu, Yang-sheng Wu, Feng-cai Zhu, et al.
Infectious Diseases & Immunity|April 17, 2024
The COVID-19 Vaccine in Clinical Trials: Where Are We Now?Hu-Dachuan Jiang, Jing-Xin Li, Peng Zhang, et al.
Expert Review of Vaccines|March 14, 2014
Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trialsJing-Xin Li, Qun-Ying Mao, Zheng-Lun Liang, et al.
Expert Review of Vaccines|May 22, 2016
Enterovirus 71: a whole virion inactivated enterovirus 71 vaccineYang Zhou, Jing-Xin Li, Peng-Fei Jin, et al.
Human Vaccines & Immunotherapeutics|December 3, 2020
Safety and immunogenicity of meningococcal (Groups A and C) polysaccharide vaccine in children 2 to 6 y of age in China: a randomized, active-controlled, non-inferiority studyFeng-Cai Zhu, Yue-Mei Hu, Ya-Nan Li, et al.
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
Zhongguo Yi Miao He Mian Yi|August 24, 2010
[Research progress of influenza type A(H1N1) vaccine and monitoring adverse reaction]Wei-wei Zhang, Liang Li, Feng-cai Zhu
Expert Review of Vaccines|October 1, 2016
Vaccine profile of PPV23: Beijing Minhai Biotech 23-valent pneumococcal vaccineQi Liang, Gui-Fan Li, Feng-Cai Zhu
Zhongguo Yi Miao He Mian Yi|January 21, 2010
[Safety and immunogenicity of rabies vaccine (chick embryo cell) for human use produced in Germany and India]Feng-Cai Zhu, Chuan-Hong Wu, Fan-Yue Meng
Human Vaccines & Immunotherapeutics|April 5, 2019
The vaccines-associated Arthus reactionBaozhen Peng, Mingwei Wei, Feng-Cai Zhu, et al.
Expert Review of Vaccines|May 27, 2017
Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpointsWenbo Zhu, Pengfei Jin, Jing-Xin Li, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|April 17, 2003
[Surveillance on hemorrhagic fever with renal syndrome in Jiangsu province from 1996 to 2000]Rong-qiang Zu, Yang-sheng Wu, Feng-cai Zhu, et al.
Infectious Diseases & Immunity|April 17, 2024
The COVID-19 Vaccine in Clinical Trials: Where Are We Now?Hu-Dachuan Jiang, Jing-Xin Li, Peng Zhang, et al.
Expert Review of Vaccines|March 14, 2014
Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trialsJing-Xin Li, Qun-Ying Mao, Zheng-Lun Liang, et al.
Expert Review of Vaccines|May 22, 2016
Enterovirus 71: a whole virion inactivated enterovirus 71 vaccineYang Zhou, Jing-Xin Li, Peng-Fei Jin, et al.
Human Vaccines & Immunotherapeutics|December 3, 2020
Safety and immunogenicity of meningococcal (Groups A and C) polysaccharide vaccine in children 2 to 6 y of age in China: a randomized, active-controlled, non-inferiority studyFeng-Cai Zhu, Yue-Mei Hu, Ya-Nan Li, et al.
Pageof 12